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It was highlighted that the original article \[[@CR1]\] contained the below errors in Tables [2](#Tab1){ref-type="table"}, [3](#Tab2){ref-type="table"} and [4](#Tab3){ref-type="table"} and in the legends of Tables [3](#Tab2){ref-type="table"} and [4](#Tab3){ref-type="table"}. This Correction article shows the correct Tables and legends. In Table [2](#Tab1){ref-type="table"}, for Stage I -- SCSTs the number for "uninsured" and "privately insured" was swapped. The distribution should be uninsured = 20 (8%); privately insured = 169 (65%)In Table [3](#Tab2){ref-type="table"}, multivariable HR for Uninsured should read HR 2.31, 95% CI 2.01--2.66. Additionally, Urban/Rural should read HR 1.13, 95% CI 1.00--1.29. Among those with Stage II/III tumors, for percent of individuals in the patient's ZIP code without a high school diploma, the less than 7% group should read HR 0.67, 95% CI 0.52--0.88. In Table [4](#Tab3){ref-type="table"}, for stage II/III, HR for income \>\$63 k should read HR 0.79, 95% CI 0.61--1.02. Additionally, for stage II/III, for percent of individuals in the patient's ZIP code without a high school diploma, the less than 7% group should read HR 0.67, 95% CI 0.52--0.88.In Table [4](#Tab3){ref-type="table"}, for stage II/III, HR for income \>\$63 k should read HR 0.79, 95% CI 0.61--1.02. Additionally, for stage II/III, for percent of individuals in the patient's ZIP code without a high school diploma, the less than 7% group should read HR 0.67, 95% CI 0.52--0.88.Table legend corrections: For Table [3](#Tab2){ref-type="table"}, the definition of the abbreviation "IQR" is unnecessary. Table [4](#Tab3){ref-type="table"} was missing the following - CI = Confidence interval, GCTs = Germ cell tumors, HR = Hazard ratio, SCSTs = Sex cord stromal tumors, \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001Table 2Stage-specific comparison of the sociodemographic and clinical characteristics of patients with SCSTs versus GCTsFactorStage IStage II/IIISCSTsGCTs***p***-valueSCSTsGCTsp-valueN25932,204219708Age at diagnosis, median (IQR)43 (34, 57)34 (28, 43)\< 0.00155 (42, 64)33 (26, 42)\< 0.001Diagnosis year\< 0.0010.38 2004--200546 (18%)6387 (20%)2 (10%)1780 (18%) 2006--200733 (13%)6416 (20%)6 (29%)1874 (19%) 2008--200945 (17%)6528 (20%)5 (24%)1942 (20%) 2010--201175 (29%)6487 (20%)6 (29%)1993 (21%) 2012--201360 (23%)6386 (20%)2 (10%)2119 (22%)Race/ethnicity\< 0.0010.62 Non-Hispanic White157 (61%)25,125 (78%)17 (81%)7266 (75%) Non-Hispanic Black47 (18%)809 (3%)1 (5%)311 (3%) Hispanic/Other52 (20%)5672 (18%)3 (14%)2000 (21%) Unknown3 (1%)598 (2%)0 (0%)131 (1%)Insurance\< 0.0010.087 Uninsured**20 (8%)**3411 (11%)4 (19%)1351 (14%) Private insurance**169 (65%)**24,575 (76%)9 (43%)6339 (65%)Medicaid/Medicare/other government insurance62 (24%)3605 (11%)8 (38%)1812 (19%) Unknown8 (3%)613 (2%)0 (0%)206 (2%)Income (per year)0.380.68 Less than \$38 k40 (15%)3981 (12%)5 (24%)1507 (16%) \$38 k-62,999115 (44%)15,408 (48%)10 (48%)4791 (49%) \$63 k or greater100 (39%)12,407 (39%)6 (29%)3256 (34%) Unknown4 (2%)408 (1%)0 (0%)154 (2%)Percent in ZIP code without a high school degree0.690.75 21% or greater37 (14%)4450 (14%)5 (24%)1711 (18%) 7--20.9%147 (57%)17,658 (55%)12 (57%)5355 (55%) Less than 7%71 (27%)9716 (30%)4 (19%)2496 (26%) Unknown4 (2%)380 (1%)0 (0%)146 (2%)Residence0.420.51 Metropolitan221 (85%)26,877 (84%)16 (76%)7934 (82%) Urban/rural38 (15%)5327 (17%)5 (24%)1774 (18%)Charlson-Deyo comorbidity score0.016\< 0.001 0237 (92%)30,544 (95%)15 (71%)9029 (93%) 1 or more22 (9%)1660 (5%)6 (29%)679 (7%)Stage0.21 Stage I259 (100%)32,204 (100%)---- Stage II----9 (43%)5469 (56%) Stage III----12 (57%)4239 (44%)Treatment\< 0.001\< 0.001 No orchiectomy0 (0%)30 (0.1%)2 (10%)634 (7%) Orchiectomy alone250 (97%)16,519 (51%)10 (48%)1106 (11%) Orchiectomy + adjuvant therapy9 (4%)15,626 (49%)9 (43%)7941 (82%) Other/unknown0 (0%)29 (0.1%)0 (0%)27 (0.3%)Last contact or death, months from diagnosis, median (IQR)*N* = 229*N* = 28,855\< 0.001*N* = 20*N* = 86120.00241 (22, 62)53 (29, 80)19 (8, 55)47 (24, 75)Time from diagnosis to death, median (IQR)*N* = 13*N* = 747*N* = 14*N* = 86623 (18, 43)31 (14, 58)0.7811 (7, 21)13 (4, 28)0.96GCTs = Germ cell tumors, IQR = Interquartile range, SCSTs = Sex cord stromal tumorsTable 3Univariable and multivariable Cox proportional hazards regression analysis on the association between sociodemographic and clinical characteristics and mortality of the overall cohortUnivariable HR (95% CI)Multivariable^1^ HR (95% CI) -- Overall**Tumor type** GCTsRef.Ref. SCSTs2.96 (2.03--4.33)\*\*\*1.68 (1.13--2.49)\***Age (per 5-year increase)**1.21 (1.19--1.23)\*\*\*1.18 (1.16--1.20)\*\*\***Race/ethnicity** Non-Hispanic WhiteRef.Ref. Non-Hispanic Black1.80 (1.41--2.29)\*\*\*1.13 (0.89--1.45) Hispanic/other1.27 (1.13--1.43)\*\*\*1.14 (1.01--1.30)\***Insurance** Private insuranceRef.Ref. Uninsured2.63 (2.29--3.01)\*\*\***2.31** (2.01--2.66)\*\*\*Medicaid/Medicare/other government insurance4.33 (3.88--4.83)\*\*\*2.72 (2.42--3.05)\*\*\***Income (per year)**  \< \$38,000Ref.Ref. \$38,000--\$62,9990.71 (0.62--0.81)\*\*\*0.94 (0.82--1.09)  \> \$63,0000.44 (0.38--0.50)\*\*\*0.76 (0.63--0.92)\*\***Percent in ZIP code without a high school diploma**  \> 21%Ref.Ref. 7--20.9%0.63 (0.56--0.71)\*\*\*0.83 (0.73--0.96)\*  \< 7%0.43 (0.37--0.49)\*\*\*0.74 (0.61--0.90)\*\***Residence** MetropolitanRef.Ref. Urban/rural1.49 (1.33--1.67)\*\*\*1.13 (1.00--**1.29**)**Charlson-Deyo comorbidity score** 0Ref.Ref.  [\>]{.ul} 13.23 (2.82--3.70)\*\*\*2.06 (1.79--2.37)\*\*\*CI = Confidence interval, GCTs = Germ cell tumors, HR = Hazard ratio, SCSTs = Sex cord stromal tumors\**p* \< 0.05\*\**p* \< 0.01\*\*\**p* \< 0.001^1^The following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code without a high school diploma, residence, Charlson-Deyo comorbidity scoreTable 4Multivariable Cox proportional hazards regression analysis on the association between sociodemographic and clinical characteristics and mortality by stageMultivariable^1^ HR (95% CI) -- Stage IMultivariable^1^ HR (95% CI) -- Stage II/III**Tumor type** GCTsRef.Ref. SCSTs1.06 (0.60--1.86)3.28 (1.88--5.73)\*\*\***Age (per 5-year increase)**1.23 (1.20--1.26)\*\*\*1.13 (1.10--1.16)\*\*\***Race/ethnicity** Non-Hispanic WhiteRef.Ref. Non-Hispanic Black1.18 (0.80--1.72)1.13 (0.81--1.56) Hispanic/other1.14 (0.95--1.38)1.12 (0.94--1.32)**Insurance** Private insuranceRef.Ref. Uninsured2.58 (2.08--3.21)\*\*\*2.07 (1.72--2.50)\*\*\* Medicaid/Medicare/other government insurance3.15 (2.64--3.75)\*\*\*2.31 (1.97--2.70)\*\*\***Income (per year)**  \< \$38,000Ref.Ref. \$38,000--\$62,9990.92 (0.74--1.15)0.96 (0.79--1.16)  \> \$63,0000.74 (0.56--0.98)\***0.79** (0.61--1.02)**Percent in ZIP code without a high school diploma**  \> 21%Ref.Ref. 7--20.9%0.87 (0.70--1.07)0.80 (0.67--0.97)\*  \< 7%0.80 (0.61--1.06)**0.67** (0.52--0.88)\*\***Residence** MetropolitanRef.Ref. Urban/rural1.18 (0.98--1.42)1.09 (0.91--1.29)**Charlson-Deyo comorbidity score** 0Ref.Ref.  [\>]{.ul} 12.03 (1.64--2.51)\*\*\*2.03 (1.68--2.45)\*\*\***CI = Confidence interval, GCTs = Germ cell tumors, HR = Hazard ratio, SCSTs = Sex cord stromal tumors\**p*** **\< 0.05\*\**p*** **\< 0.01\*\*\**p*** **\< 0.001**^1^The following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code without a high school diploma, residence, Charlson-Deyo comorbidity score
